بررسی نسبت فراوانی پلاسنتا آکرتا در زنان کاندیدای سزارین غیراورژانسی با سابقه سزارین قبلی مراجعه کننده به بیمارستان‌های زنان سطح شهر تبریز: 95-1391

نوع مقاله : اصیل پژوهشی

نویسندگان

1 دانشیار گروه زنان و مامایی، دانشکده پزشکی، دانشگاه علوم پزشکی تبریز، تبریز، ایران.

2 دانشیار گروه بیهوشی، دانشکده پزشکی، دانشگاه علوم پزشکی تبریز، تبریز، ایران.

3 متخصص زنان و زایمان، دانشکده پزشکی، دانشگاه علوم پزشکی تبریز، تبریز، ایران.

چکیده

مقدمه: عدم اطلاع از شیوع پلاسنتا آکرتا موجب بروز عوارض ناخواسته در زنان مستعد می‌شود و آگاهی از شیوع این عارضه می‌تواند روش‌های تشخیصی و درمانی در زنان مستعد را در مطالعات آتی تضمین نماید؛ لذا مطالعه حاضر با هدف بررسی نسبت فراوانی پلاسنتا آکرتا در زنان کاندید سزارین غیراورژانسی با سابقه سزارین قبلی مراجعه‌کننده به بیمارستان‌های زنان سطح شهر تبریز انجام شد.
روش‌کار: این مطالعه توصیفی تحلیلی در طی سال‌های 95-1391 در دو بیمارستان الزهراء و طالقانی تبریز با مشارکت 310 زن کاندید سزراین غیراورژانسی انجام شد. اطلاعات هر فرد شامل اطلاعات جمعیت‌شناختی و اطلاعات مربوط به بیماری در چک‌لیست پژوهشگر ساخته وارد شد. تجزیه و تحلیل داده‌ها با استفاده از نرم‌افزار آماری SPSS (نسخه 20) و آزمون‌های آماری رگرسیون و همبستگی اسپیرمن انجام شد. میزان p کمتر از 05/0 معنادار در نظر گرفته شد.
یافته‌ها: 55 نفر (74/17%) به پلاسنتا آکرتا مبتلا بودند و متغیرهایی نظیر سن (001/0=p)، شاخص توده بدنی (003/0=p)، تعداد سزارین قبلی (002/0=p)، مصرف سیگار (036/0=p)، تعداد بارداری قبلی (002/0=p)، سابقه میومکتومی (001/0=p)، خونریزی در سه ماهه سوم (003/0=p) و تعداد قل‌های حین زایمان (001/0=p) با ابتلاء به پلاسنتا آکرتا ارتباط آماری معناداری داشتند.
نتیجه‌گیری: شیوع پلاسنتا آکرتا در مطالعه حاضر 74/17% بود که انجام اقدامات تشخیصی دقیق جهت اطلاع از این عارضه را ضروری می‌نماید.

کلیدواژه‌ها

عنوان مقاله [English]

Prevalence rate of placenta accreta in women candidates for non-emergency cesarean section with previous cesarean section referred to Tabriz Women's Hospitals: 2012-2016

نویسندگان [English]

  • Fatemeh Abasalizadeh 1
  • Shamsi Abasalizadeh 2
  • Ladan Kalafi 3
1 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Associate Professor, Department of Anesthesiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Gynecologist, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
چکیده [English]

Introduction: Lack of knowledge about the prevalence of placenta accreta causes unintended complications in susceptible women. Awareness of its prevalence can guarantee the diagnostic and therapeutic methods in susceptible women in future studies. This study was performed with aim to evaluate the prevalence rate of placenta accreta in women candidate for non-emergency cesarean section with previous cesarean section referred to Tabriz women's hospitals.
Methods: This descriptive-analytical study was performed during 2012-2016 at Tabriz two hospitals of Al-Zahra and Taleghani with the participation of 310 women candidate for non-emergency cesarean. The individual information including demographic characteristics and disease-related information was included in the researcher-made checklist. Data were analyzed using SPSS software (version 20) and Spearman correlation and regression tests. PResults: 55 patients (17.74%) had placenta accreta; the variables such as age (P=0.001), BMI (P=0.003), number of previous cesarean section (P=0.002), cigarette smoking (P=0.036), number of previous pregnancies (P=0.002), history of myomectomy (P=0.001), third trimester hemorrhage (P=0.003), and number of baby during delivery (P=0.003) were significantly associated with placenta accreta.
Conclusion: The prevalence of placenta accreta was 17.74% in the present study, which necessitates doing precise diagnostic measures to be aware of this complication.

کلیدواژه‌ها [English]

  • Elective cesarean section
  • Placenta accreta
  • Prevalence
  • Risk factor

مراجع

  1. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol 2017; 217(1):27-36.
  2. Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, Sisodia RC, Gervais DA, Lee SI. MRI of placenta accreta, placenta increta, and placenta percreta: pearls and pitfalls. AJR Am J Roentgenol 2017; 208(1):214-221.
  3. Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and metaanalysis. Am J Obstet Gynecol 2019; 221(3):208-218.
  4. Fox KA, Shamshirsaz AA, Carusi D, Secord AA, Lee P, Turan OM, et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol 2015; 213(6):755-60.
  5. Palacios-Jaraquemada JM, D’Antonio F, Buca D, Fiorillo A, Larraza P. Systematic review on near miss cases of placenta accreta spectrum disorders: correlation with invasion topography, prenatal imaging, and surgical outcome. J Matern Fetal Neonatal Med 2019:1-8.
  6. Daney de Marcillac F, Lecointre L, Guillaume A, Sananes N, Fritz G, Viville B, et al. Maternal morbidity and mortality associated with conservative management for placenta morbidly adherent (accreta) diagnosed during pregnancy. Report of 15 cases. J Gynecol Obstet Biol Reprod (Paris) 2016; 45(8):849-858.
  7. Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers 2018; 2018:1507674.
  8. De Mucio B, Serruya S, Alemán A, Castellano G, Sosa CG. A systematic review and meta‐analysis of cesarean delivery and other uterine surgery as risk factors for placenta accreta. Int J Gynaecol Obstet 2019.
  9. Goh WA, Zalud I. Placenta accreta: diagnosis, management and the molecular biology of the morbidly adherent placenta. J Matern Fetal Neonatal Med 2016; 29(11):1795-800.
  10. Muthyala T, Rathore A, Shahnaz G, Kumar D, Singh P, Bhasin S. Does morbidly adherent placenta mask hypertension in pregnancy–a case report and review of literature. J Obstet Gynaecol 2019; 39(7):1019-1021.
  11. Iacovelli A, Liberati M, Khalil A, Timor-Trisch I, Leombroni M, Buca D, et al. Risk factors for abnormally invasive placenta: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2018:1-11.
  12. Kollmann M, Gaulhofer J, Lang U, Klaritsch P. Placenta praevia: incidence, risk factors and outcome. J Matern Fetal Neonatal Med 2016; 29(9):1395-8.
  13. Aghamohammadi D, Mehdinavaz Aghdam A, Khanbabayi Gol M. Prevalence of Infections Associated with Port and Predisposing Factors in Women with Common Cancers Under Chemotherapy Referred to Hospitals in Tabriz in 2015. Iran J Obstet Gynecol Infertil 2019; 21(11):7-13.
  14. Alvandfar D, Alizadeh M, Khanbabayi Gol M. Prevalence of pregnancy varicose and its effective factors in women referred to gynecology hospitals in Tabriz. Iran J Obstet Gynecol Infertil 2019; 22(9):1-7.
  15. Khanbabaei Gol M, Aghamohammadi D. Effect of intravenous infusion of magnesium sulfate on opioid use and hemodynamic status after hysterectomy: double-blind clinical trial. Iran J Obstet Gynecol Infertil 2019; 22(7):32-38.
  16. Khanbabaei Gol M, Mobaraki-Asl N, Ghavami Z, Zharfi M, Mehdinavaz Aghdam A. Sexual Violence against Mastectomy Women Improved from Breast Cancer. Iran J Obstet Gynecol Infertil 2019; 22(5):52-60.
  17. Khanbabaei Gol M, Rezvani F, Ghavami Z, Mobaraki-Asl N. Prevalence of neuropathic pain and factors affecting sleep quality in women with breast cancer after radiotherapy. Iran J Obstet Gynecol Infertil 2019; 22(6):46-53.
  18. Montazer M, Hadadi Z, Ghavami Z, Khanbabaei Gol M. Relationship of Body Mass Index with Chronic Pain after Breast Surgery in Women with Breast Cancer. Iran J Obstet Gynecol Infertil 2019; 22(8):10-18.
  19. Gol MK, Dorosti A, Montazer M. Design and psychometrics cultural competence questionnaire for health promotion of Iranian nurses. J Educ Health Promot 2019; 8:155.
  20. Mobaraki-Asl N, Ghavami Z, Khanbabayi Gol M. Development and validation of a cultural competence questionnaire for health promotion of Iranian midwives. J Educ Health Promot 2019; 8(1):179.
  21. Haghdoost M, Mousavi S, Khanbabayi Gol M, Montazer M. Frequency of Chlamydia trachomatis Infection in Spontaneous Abortion of Infertile Women During First Pregnancy Referred to Tabriz University of Medical Sciences by Nested PCR Method in 2015. International Journal of Women’s Health and Reproduction Sciences 2019; 7(4):526-530.
  22. Aghamohamadi D, Khanbabayi Gol M. An Investigation Into the Effects of Magnesium Sulfate on the Complications of Succinylcholine Administration in Nulliparous Women Undergoing Elective Cesarean Section: A Double-Blind Clinical Trial. International Journal of Women’s Health and Reproduction Sciences 2019; 7(4):520-525.
  23. Aslanabadi S, Djalilian H, Zarrintan S, Sokhandan M, Hashem-Zadeh H, Lotfi AR. Supernumerary nostril together with esophageal atresia, imperforate anus and patent ductus arteriosus: a case report and review of the literature. Pediatr Surg Int 2009; 25(5):433-6.
  24. Kermani IA, Seifi Sh, Dolatkhah R, Sakhinia E, Dastgiri S, Ebrahimi A, et al. Human papilloma virus in head and neck squamous cell cancer. Iran J Cancer Prev 2012; 5(1):21-26.
  25. Farzaneh F, Esmailzadeh A. Placenta Accreta at 15 Weeks of Gestational Age and Uterus Preservation with Hysterectomy Abortion. Zahedan J Res Med Sci 2017; 19(10):e10830.
  26. Mehrabadi A, Hutcheon JA, Liu S, Bartholomew S, Kramer MS, Liston RM, et al. Contribution of placenta accreta to the incidence of postpartum hemorrhage and severe postpartum hemorrhage. Obstet Gynecol 2015; 125(4):814-21.
  27. Farquhar CM, Li Z, Lensen S, McLintock C, Pollock W, Peek MJ, et al. Incidence, risk factors and perinatal outcomes for placenta accreta in Australia and New Zealand: a case–control study. BMJ open 2017; 7(10):e017713.
  28. Vahanian SA, Lavery JA, Ananth CV, Vintzileos A. Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. Am J Obstet Gynecol 2015; 213(4 Suppl):S78-90.
  29. Jauniaux E, Burton GJ. Pathophysiology of Placenta Accreta Spectrum Disorders: A Review of Current Findings. Clin Obstet Gynecol 2018; 61(4):743-754.
  30. Melcer Y, Jauniaux E, Maymon S, Tsviban A, Pekar-Zlotin M, Betser M, et al. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. Am J Obstet Gynecol 2018; 218(4):443. .e1-443.e8.
  31. Jauniaux E, Chantraine F, Silver RM, Langhoff‐Roos J, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int J Gynecol Obstet 2018; 140(3):265-273.
  32. Lockwood CJ, Russo-Stieglitz K. Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality. Recuperado de https://www uptodate com/contents/placenta-previa-epidemiology-clinical-featuresdiagnosis-morbidity-andmortality; 2018:2-10.
  33. Carusi DA. The Placenta Accreta Spectrum: Epidemiology and Risk Factors. Clin Obstet Gynecol 2018; 61(4):733-742.
  34. Carusi DA. Placenta Accreta: Epidemiology and Risk Factors.  Placenta Accreta Syndrome: CRC Press; 2017:11-22.
  35. Balayla J, Desilets J, Shrem G. Placenta previa and the risk of intrauterine growth restriction (IUGR): a systematic review and meta-analysis. J Perinat Med 2019; 47(6):577-584.
  36. Aydin C, Yalcin SE, Yalcin Y, Uysal D, Akkurt MO, Yavuz A, et al. Risk factors of placenta previa: a population based study and the review of the literature. Med Science 2016; 5(4):941-4.

مجله زنان، مامایی و نازایی ایران
دوره 22، شماره 11
بهمن 1398
صفحه 1-7

فایل ها

هم رسانی

ارجاع به این مقاله

آمار